PARP1 and neoplasm: As expected, IHC analysis of combination treatment indicated that the expression of activating c-RAF protein level was effectively reduced, whereas, the expression of apoptotic markers (p-c-RAF, cl-Caspase3 and cl-PARP) was induced in the combination treatment group as compared to 4-AAQB alone and cetuximab treatment and vehicle control (Figure 6E) resulting in the reduction of tumor burden in the xenograft mouse model.